Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...

Florida physician Stephen Andrew Leedy, MD, has been accused of producing child sexual abuse materials and enticing minors to ...

U.S. pharmaceutical company pays $4.07 million to resolve allegations that it violated the False Claims Act (FCA) by failing ...

DelveInsight's Mild Cognitive Impairment Market Insights report includes a comprehensive understanding of current treatment practices, mild cognitive impairment emerging drugs, market share of ...

According to DelveInsight's analysis, the mild cognitive impairment market is anticipated to increase during the forecast period (2024-2034), owing to the rise in the launch of emerging therapies ...

Stressing the importance of integrity in taxpayer-funded biomedical research, the U.S. Department of Justice reported that Athira Pharma Inc. agreed to pay more than $4 million to resolve False Claims ...

Bothell-based biopharmaceutical company Athira Pharma Inc. (Nasdaq: ATHA) is paying a $4.1 million fine due to allegations it ...

Seattle-area biotech company Athira Pharma agreed to pay $4.07 million to settle allegations that it violated the False ...

A biopharmaceutical company, Athira Pharma, settled for $4.068 million over allegations of research misconduct.

Athira Pharma (ATHA) agreed to pay $4,068,698 to resolve allegations that it violated the False Claims Act by failing to report allegations of ...

The FDA published its first draft guidance on the use of AI in the development of drugs and biological products ...

U.S. federal authorities charged a South Korean cryptocurrency mogul with defrauding investors of more than $40 billion ...